Literature DB >> 20950071

Health-state utility values in breast cancer.

Tessa Peasgood1, Sue E Ward, John Brazier.   

Abstract

Health-related quality of life is an important issue in the treatment of breast cancer and health-state utility values are essential for cost-utility analysis. A literature review was conducted to identify published values for common health states for breast cancer. In total, 13 databases were searched and 49 articles were identified providing 476 unique utility values. Where possible mean utility estimates were pooled using ordinary least squares with utilities clustered within study group and weighted by both number of respondents and inverse of the variance of each utility. Regressions included controls for disease state, utility assessment method and other features of study design. Utility values found in the review were summarized for six categories: screening-related states; preventative states; adverse events in breast cancer and its treatment; nonspecific breast cancer; metastatic breast cancer states; and early breast cancer states. The large number of values identified for metastatic breast cancer and early breast cancer states enabled data to be synthesized by meta-regression. Utilities were found to vary significantly between valuation methods and depending on who conducted the valuation. For metastatic breast cancer, values significantly varied by severity of condition, treatment and side-effects. Despite the numerous studies it is not feasible to generate a definitive list of health-state utility values that can be used in future economic evaluations owing to the complexity of the health states involved and the variety of methods used to obtain values. Future research into quality of life in breast cancer should make greater use of validated generic preference-based measures for which public preferences exist.

Entities:  

Mesh:

Year:  2010        PMID: 20950071     DOI: 10.1586/erp.10.65

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  43 in total

1.  Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses.

Authors:  Nathaniel Hendrix; David D Kim; Krishna S Patel; Beth Devine
Journal:  Med Decis Making       Date:  2021-01-15       Impact factor: 2.583

2.  Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.

Authors:  Verin Lertjanyakun; Nathorn Chaiyakunapruk; Susumu Kunisawa; Yuichi Imanaka
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

3.  Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada.

Authors:  S Djalalov; J Beca; E Amir; M Krahn; M E Trudeau; J S Hoch
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 4.  A Primer on Bayesian Decision Analysis With an Application to a Kidney Transplant Decision.

Authors:  Richard Neapolitan; Xia Jiang; Daniela P Ladner; Bruce Kaplan
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

5.  Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists.

Authors:  Michael J Zoratti; A Simon Pickard; Peep F M Stalmeier; Daniel Ollendorf; Andrew Lloyd; Kelvin K W Chan; Don Husereau; John E Brazier; Murray Krahn; Mitchell Levine; Lehana Thabane; Feng Xie
Journal:  Eur J Health Econ       Date:  2021-04-11

6.  Losing sight of the wood for the trees: some issues in describing and valuing health, and another possible approach.

Authors:  Paul Dolan; Henry Lee; Tessa Peasgood
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

7.  Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.

Authors:  H Amarens Geuzinge; Inge-Marie Obdeijn; Emiel J T Rutgers; Sepideh Saadatmand; Ritse M Mann; Jan C Oosterwijk; Rob A E M Tollenaar; Diderick B W de Roy van Zuidewijn; Marc B I Lobbes; Martijne van 't Riet; Maartje J Hooning; Margreet G E M Ausems; Claudette E Loo; Jelle Wesseling; Ernest J T Luiten; Harmien M Zonderland; Cees Verhoef; Eveline A M Heijnsdijk; Madeleine M A Tilanus-Linthorst; Harry J de Koning
Journal:  JAMA Oncol       Date:  2020-09-01       Impact factor: 31.777

Review 8.  Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Hazel Squires; Matt Stevenson; Emma Simpson; Rebecca Harvey; John Stevens
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

9.  Breast Cancer in Young Women: Health State Utility Impacts by Race/Ethnicity.

Authors:  Justin G Trogdon; Donatus U Ekwueme; Linda Chamiec-Case; Gery P Guy
Journal:  Am J Prev Med       Date:  2016-02       Impact factor: 5.043

Review 10.  The Use of Health State Utility Values in Decision Models.

Authors:  Roberta Ara; John Brazier; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.